PMID- 35466316
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2022
DP  - 2022
TI  - Three-Dimensional Conformal Radiotherapy Combined with Gemcitabine and Docetaxel 
      in the Treatment of Advanced Bladder Cancer and Its Effects on Inflammatory 
      Factors and Immune Function.
PG  - 9347218
LID - 10.1155/2022/9347218 [doi]
LID - 9347218
AB  - OBJECTIVE: To assess the efficacy of three-dimensional conformal radiotherapy 
      (3D-CRT) combined with GT chemotherapy (gemcitabine+docetaxel) in the treatment 
      of advanced bladder cancer and its influence on inflammatory factors and immune 
      function. METHODS: A total of 42 elderly patients with advanced bladder cancer 
      who were admitted to our hospital from January 2019 to January 2020 were included 
      and assigned to the GT group (21 cases) receiving GT chemotherapy and combination 
      group (21 cases) given 3D-CRT combined with GT chemotherapy. The clinical 
      efficacy, immune function, inflammatory factors, tumor markers, urinary 
      angiogenesis molecules before and after treatment, 1-year survival rate, 2-year 
      survival rate, and incidence of adverse reactions of the two groups were 
      compared. SPSS 22.0 statistical software was used for data processing and 
      analysis. RESULTS: The combination group had 5 cases of CR, 12 cases of PR, 3 
      cases of SD, and 1 case of PD, with an ORR of 80.95% (17/21), which was 
      remarkably higher than the ORR of 57.14% (12/21) in the GT group which had 3 
      cases of CR, 9 cases of PR, 5 cases of SD, and 4 cases of PD (P < 0.05). The 
      1-year survival rate of the combination group was 76.19% (16/21), and the 2-year 
      survival rate was 47.62% (10/21), which were higher than the 1-year survival rate 
      of 47.62% (10/21) and 2-year survival rate of 19.05% (4/21) in the GT group (P < 
      0.05). The two groups presented similar results in terms of adverse reactions 
      rate (P > 0.05). After treatment, the combination group obtained significantly 
      lower levels of urinary bladder cancer antigen (UBC), nuclear matrix protein-22 
      (NMP-22), vascular endothelial growth factor (VEGF), and basic fibroblast growth 
      factor (bFGF) than the GT group (P < 0.05). The CD3+, CD4+, and CD4+/CD8+ levels 
      of the two groups of patients were lower than those before treatment (P < 0.05), 
      but no statistical difference was observed between the two groups after treatment 
      (P > 0.05). The levels of interleukin-6 (IL-6) and interferon-gamma (IFN-gamma) of the 
      two groups witnessed a decline after treatment, with lower results in the 
      combination group as compared to the control group (P < 0.05). Before treatment, 
      no significant difference in the Generic Quality of Life Inventory-74 (GQOLI-74) 
      score between the two groups was found (P > 0.05). After treatment, the 
      combination group had higher GQOLI-74 scores than the GT group (P < 0.05). 
      CONCLUSION: 3D-CRT combined with GT chemotherapy yields a significant effect on 
      the treatment of elderly advanced bladder cancer by effectively protecting immune 
      function, mitigating inflammation, inhibiting tumor marker levels and the 
      expression of angiogenic molecules, and improving patients' survival.
CI  - Copyright (c) 2022 Jianwei Li et al.
FAU - Li, Jianwei
AU  - Li J
AUID- ORCID: 0000-0002-1376-0661
AD  - 2nd Department of Urology, Cangzhou Central Hospital, Cangzhou, China.
FAU - Liu, Min
AU  - Liu M
AD  - 2nd Department of Urology, Cangzhou Central Hospital, Cangzhou, China.
FAU - Sun, Pengyu
AU  - Sun P
AD  - 2nd Department of Urology, Cangzhou Central Hospital, Cangzhou, China.
FAU - Zhao, Wanli
AU  - Zhao W
AD  - 2nd Department of Urology, Cangzhou Central Hospital, Cangzhou, China.
FAU - Song, Miaomiao
AU  - Song M
AD  - 2nd Department of Urology, Cangzhou Central Hospital, Cangzhou, China.
FAU - Liu, Yang
AU  - Liu Y
AD  - 2nd Department of Urology, Cangzhou Central Hospital, Cangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220414
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC9023190
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/04/26 06:00
MHDA- 2022/04/26 06:01
PMCR- 2022/04/14
CRDT- 2022/04/25 06:14
PHST- 2021/12/23 00:00 [received]
PHST- 2022/02/28 00:00 [accepted]
PHST- 2022/04/25 06:14 [entrez]
PHST- 2022/04/26 06:00 [pubmed]
PHST- 2022/04/26 06:01 [medline]
PHST- 2022/04/14 00:00 [pmc-release]
AID - 10.1155/2022/9347218 [doi]
PST - epublish
SO  - J Oncol. 2022 Apr 14;2022:9347218. doi: 10.1155/2022/9347218. eCollection 2022.